EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsMG is a founder, member of the board, equity holder, and consultant for Forcefield Therapeutics, London, FB is a consultant of the same company. The AAV secretome library and the FunSel technology are owned by Purespring Therapeutics, for which MG is a cofounder, observer to the board, equity holder, and consultant. Competing interests MG is a founder, member of the board, equity holder, and consultant for Forcefield Therapeutics, London, FB is a consultant of the same company. The AAV secretome library and the FunSel technology are owned by Purespring Therapeutics, for which MG is a cofounder, observer to the board, equity holder, and consultant."

"Funding This work was supported by grants AIRC IG2020 Id24529 and IG2016 Id19032 to S.Z. and by Italian University and Research Ministry PRIN-2017HWTP2K, the Italian Ministry of Health RF-2019-12368718, and grants from the Fondazione AIRC IG grant 22174 and the Fondazione AIRC Special Program Molecular Clinical Oncology “5 permille” grant 22759 to G.D.S."